awards grant
- 'Open-Label, Study to Evaluate Eff and Safety of Sofosbuvir/Ledipasvir Fdc + Rbv for 12 Wks in Chronic Geno 1 HCV Subje
- ...Ambrisentan and Tadalafil Combination Therapy in Subjectswith Pulmonary Arterial Hypertension
- ...Gs-9451, Peginterferon Alfa 2a (Peg, Pegasys) and Riboviron (Rbv,Copegus) With/Without Tegobuvir (Gs9190)...
- A Long Term Follow-Up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored
- A Long Term Follow-Up Registry for Subjects Who Did Not Achiieve a Susstained Virologic Response to Treatment in Gilead-
- A Phase 1B, Rndm...Single Doses of Gs-9256 in Subjects With Chronic Hepatitis C Genotpye I Infection
- A Phase 2 Open Label Multicenter Multicohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir
- A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naïve Subjects with Chronic Genotype1 HCV Infection
- A Phase 2 Randomoized Double Blind Placobo Controlled Multicenter Dose Ranging Study of Cicletanine in Subjects With....
- A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection
- A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + Gs-5816 for 12 Weeks in Treatment Experienced Subjects with Chronic HCV Infection
- A Phase 2, Open-Label, Multicenter, Multi-Cohort, Single-Armstudy to Investigate the Safety and Efficacy of Sofosbuvir..
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy & Safety Ofgs-6624
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Gs
- A Phase 2/3 Multicenter, Open Label, Multicohort, Two Part Study Evaluating the Pharmacokinetics(Pk) Safety And........
- A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety and Antiviral Activity of the Elvitegravir/Cobicistat
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peg interferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 or 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peg interferon Alfa 2a (PEG, Pegasys®), and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peg interferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
- A Phase 3 Multicenter Randomized Open Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Gs-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Db/Bd Multicenter, Randomized, Placebo-Controlledtrial Evaluating Repeated Courses of Aztreonam for Inhalatio
- A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels......
- A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed-Dose . . .
- A Phase 3, Multicenter, Open-label Study to Investigate the Efficacy and Safety of GS-7977 with Peg interferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy & Saftety of Sofosbuvir/Lrdipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Saftety of Sofosbuvir/Gs-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or
- A Phase 3, Randomized, Dbl-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Gs-1101 (Cal-101).....
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Evaluating the Efficacy and Safety of Gs-1101 (Cal-101)...
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution.....
- A Phase 3,Randomized, Double-Blind, Placebo-Controlled Studye Effects of Ranolazine on Major Adverse Cardiovascular....
- A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine...
- A Randomized, Multicenter Study of First Line Ambrisentan and Tadalafil Combination Therapy in Subjects With..........
- A Randomized, Open Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed Dose Combination...
- An Opened Label Study of Gs-7977 + Ribavirin for 12 Weeks Insubjects With Chronic HCV Infection Who Participated.....
- Artemis-Ipf: a Phase 3, Rdm, D/Bd Placebo-Controlled, M/C Parallel-Group, Event-Driven Study to Evaluate the Efficacy.
- Artemis-Ph:a Phase 3, Rnd/Dbld, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy & Safety
- Athena-1: ...Ambrisentan and Sildenafil Combination Therapy in Subjects With Pulmonary Artierial Hypertension...
- Cost Effectiveness of Sofosbuvir for Hepatitis C Virus Infection: United States Adaptation Model
- Cost-Effectiveness of Sofosbuvir for Hepititis C Virus Infection: United States Adaptation Model
- Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa
- HCV-Target: Hepatitis C Therapeutic Registry and Research Network-a Longitudinal, Observational Study
- Health Economics and Outcomes Research (Heor). Work Order-3 Heor HCV
- Health Economics and Outcomes Research (Heor). Work Order-4 Heor HCV
- Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic . .
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficiacy of Tenofavir Dr As Part...
- Quantum: An International Multicenter Blinded Randomized Study to Investigate Safety Tolerability Pharmacokinetics......
- R-Wise: Treament With Ranolazine in Microvascular Coronary Disfunction (Mcd): Impact on Angina and Myocardial Ischemia
- The Comet Study: a Phase 4 Evaluation of Switching from Twice Daily Zidovudine and Lamivudine (Combivir) to a Simplified